CU24671B1 - Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación - Google Patents
Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparaciónInfo
- Publication number
- CU24671B1 CU24671B1 CU2020000053A CU20200053A CU24671B1 CU 24671 B1 CU24671 B1 CU 24671B1 CU 2020000053 A CU2020000053 A CU 2020000053A CU 20200053 A CU20200053 A CU 20200053A CU 24671 B1 CU24671 B1 CU 24671B1
- Authority
- CU
- Cuba
- Prior art keywords
- janokinase
- inhibitor
- crystalline form
- composition
- preparation process
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 PYRIMIDINE COMPOUND Chemical class 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
Abstract
<p>La invención proporciona un compuesto de Ia fórmula (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>o una sal farmacéuticamente aceptable de este, que es un inhibidor de las janocinasas (JAK), composiciones farmaceúticas que comprenden dicho compuesto y una forma cristalina, útiles para tratar enfermedades inflamatorias de Ia piel y otras enfermedades. La invención también proporciona procesos y productos intermedios útiles para preparar dicho compuesto.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577852P | 2017-10-27 | 2017-10-27 | |
| PCT/US2018/057682 WO2019084383A1 (en) | 2017-10-27 | 2018-10-26 | PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20200053A7 CU20200053A7 (es) | 2021-03-11 |
| CU24671B1 true CU24671B1 (es) | 2023-07-12 |
Family
ID=64277858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000053A CU24671B1 (es) | 2017-10-27 | 2018-10-26 | Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación |
Country Status (38)
| Country | Link |
|---|---|
| US (7) | US10308646B2 (es) |
| EP (1) | EP3672965B1 (es) |
| JP (1) | JP7218364B2 (es) |
| KR (1) | KR102613503B1 (es) |
| CN (1) | CN111247142B (es) |
| AR (1) | AR113803A1 (es) |
| AU (1) | AU2018354370B2 (es) |
| BR (1) | BR112020008015A2 (es) |
| CA (1) | CA3074034A1 (es) |
| CL (1) | CL2020001090A1 (es) |
| CR (1) | CR20200180A (es) |
| CU (1) | CU24671B1 (es) |
| DK (1) | DK3672965T3 (es) |
| DO (1) | DOP2020000083A (es) |
| EA (1) | EA202091016A1 (es) |
| EC (1) | ECSP20023795A (es) |
| ES (1) | ES2932526T3 (es) |
| GE (1) | GEP20227344B (es) |
| HR (1) | HRP20221221T1 (es) |
| HU (1) | HUE060401T2 (es) |
| IL (1) | IL274037B2 (es) |
| LT (1) | LT3672965T (es) |
| MA (1) | MA49956B1 (es) |
| MD (1) | MD3672965T2 (es) |
| MX (1) | MX2020004255A (es) |
| NI (1) | NI202000032A (es) |
| PE (1) | PE20201495A1 (es) |
| PH (1) | PH12020500528A1 (es) |
| PL (1) | PL3672965T3 (es) |
| PT (1) | PT3672965T (es) |
| RS (1) | RS63608B1 (es) |
| SG (1) | SG11202001706RA (es) |
| SI (1) | SI3672965T1 (es) |
| SM (1) | SMT202200409T1 (es) |
| TW (1) | TWI789446B (es) |
| UA (1) | UA125130C2 (es) |
| WO (1) | WO2019084383A1 (es) |
| ZA (1) | ZA202001641B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018354370B2 (en) | 2017-10-27 | 2023-04-27 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compound as JAK kinase inhibitor |
| MX2021006283A (es) * | 2018-11-30 | 2021-10-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos. |
| AR118768A1 (es) | 2019-04-24 | 2021-10-27 | Theravance Biopharma R&D Ip Llc | Derivados de pirimidina como inhibidores de las cinasas jak |
| HRP20241053T1 (hr) * | 2019-04-24 | 2024-11-08 | Theravance Biopharma R&D Ip, Llc | Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti |
| KR102891680B1 (ko) * | 2020-07-28 | 2025-11-27 | 아큐티스 바이오테라퓨틱스, 인크. | Jak 저해제 및 라우레스-4를 함유하는 국소 제형 |
| BR112023003517A2 (pt) * | 2020-08-26 | 2023-05-09 | Nalo Therapeutics | Moduladores da proteína proto-oncogênica da família myc |
| WO2022076771A1 (en) * | 2020-10-08 | 2022-04-14 | Icahn School Of Medicine At Mount Sinai | Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof |
| TW202311256A (zh) * | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| US20250051338A1 (en) | 2021-10-25 | 2025-02-13 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| MX2024007437A (es) | 2021-12-15 | 2024-09-04 | Arcutis Biotherapeutics Inc | Formulaciones estables de shr0302. |
| CN114246938A (zh) * | 2022-01-25 | 2022-03-29 | 中山大学中山眼科中心 | Il-4在制备用于治疗视网膜变性疾病药物中的应用 |
| CN115487301B (zh) * | 2022-11-08 | 2023-07-07 | 四川大学华西医院 | Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| ATE354573T1 (de) | 2000-12-21 | 2007-03-15 | Vertex Pharma | ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß |
| CA2588220A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| CA2629781A1 (en) | 2005-11-16 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| UY30444A1 (es) | 2006-06-30 | 2008-01-31 | Astrazeneca Ab | Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos. |
| CA2656290A1 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| WO2013092940A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | 2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors |
| WO2015094803A1 (en) * | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (es) | 2014-08-21 | 2018-03-31 | ||
| CN106687467A (zh) * | 2014-09-30 | 2017-05-17 | 韩美精密化学株式会社 | 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法 |
| DK3303348T3 (da) | 2015-05-28 | 2019-11-11 | Theravance Biopharma R&D Ip Llc | Naphthyridinforbindelser som JAK-kinaseinhibitorer |
| US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| AU2017258186B2 (en) | 2016-04-28 | 2020-09-17 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as JAK kinase inhibitors |
| AU2018354370B2 (en) * | 2017-10-27 | 2023-04-27 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compound as JAK kinase inhibitor |
| AR118768A1 (es) | 2019-04-24 | 2021-10-27 | Theravance Biopharma R&D Ip Llc | Derivados de pirimidina como inhibidores de las cinasas jak |
| HRP20241053T1 (hr) | 2019-04-24 | 2024-11-08 | Theravance Biopharma R&D Ip, Llc | Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti |
-
2018
- 2018-10-26 AU AU2018354370A patent/AU2018354370B2/en active Active
- 2018-10-26 MA MA49956A patent/MA49956B1/fr unknown
- 2018-10-26 TW TW107137865A patent/TWI789446B/zh active
- 2018-10-26 CA CA3074034A patent/CA3074034A1/en active Pending
- 2018-10-26 ES ES18801171T patent/ES2932526T3/es active Active
- 2018-10-26 PE PE2020000414A patent/PE20201495A1/es unknown
- 2018-10-26 BR BR112020008015-2A patent/BR112020008015A2/pt unknown
- 2018-10-26 WO PCT/US2018/057682 patent/WO2019084383A1/en not_active Ceased
- 2018-10-26 EA EA202091016A patent/EA202091016A1/ru unknown
- 2018-10-26 RS RS20220903A patent/RS63608B1/sr unknown
- 2018-10-26 SI SI201830770T patent/SI3672965T1/sl unknown
- 2018-10-26 PT PT188011712T patent/PT3672965T/pt unknown
- 2018-10-26 CU CU2020000053A patent/CU24671B1/es unknown
- 2018-10-26 UA UAA202003146A patent/UA125130C2/uk unknown
- 2018-10-26 MX MX2020004255A patent/MX2020004255A/es unknown
- 2018-10-26 IL IL274037A patent/IL274037B2/en unknown
- 2018-10-26 HU HUE18801171A patent/HUE060401T2/hu unknown
- 2018-10-26 LT LTEPPCT/US2018/057682T patent/LT3672965T/lt unknown
- 2018-10-26 DK DK18801171.2T patent/DK3672965T3/da active
- 2018-10-26 CR CR20200180A patent/CR20200180A/es unknown
- 2018-10-26 MD MDE20200681T patent/MD3672965T2/ro not_active IP Right Cessation
- 2018-10-26 SM SM20220409T patent/SMT202200409T1/it unknown
- 2018-10-26 CN CN201880068081.5A patent/CN111247142B/zh active Active
- 2018-10-26 US US16/171,693 patent/US10308646B2/en active Active
- 2018-10-26 KR KR1020207012597A patent/KR102613503B1/ko active Active
- 2018-10-26 HR HRP20221221TT patent/HRP20221221T1/hr unknown
- 2018-10-26 PL PL18801171.2T patent/PL3672965T3/pl unknown
- 2018-10-26 SG SG11202001706RA patent/SG11202001706RA/en unknown
- 2018-10-26 AR ARP180103131A patent/AR113803A1/es unknown
- 2018-10-26 EP EP18801171.2A patent/EP3672965B1/en active Active
- 2018-10-26 JP JP2020523324A patent/JP7218364B2/ja active Active
- 2018-10-26 GE GEAP201815340A patent/GEP20227344B/en unknown
-
2019
- 2019-04-22 US US16/390,175 patent/US10562894B2/en active Active
-
2020
- 2020-01-08 US US16/737,067 patent/US10774080B2/en active Active
- 2020-03-13 PH PH12020500528A patent/PH12020500528A1/en unknown
- 2020-03-16 ZA ZA2020/01641A patent/ZA202001641B/en unknown
- 2020-04-23 CL CL2020001090A patent/CL2020001090A1/es unknown
- 2020-04-24 NI NI202000032A patent/NI202000032A/es unknown
- 2020-04-27 EC ECSENADI202023795A patent/ECSP20023795A/es unknown
- 2020-05-06 DO DO2020000083A patent/DOP2020000083A/es unknown
- 2020-08-12 US US16/991,268 patent/US10988470B2/en active Active
-
2021
- 2021-03-30 US US17/301,243 patent/US11420965B2/en active Active
-
2022
- 2022-06-30 US US17/855,539 patent/US11814377B2/en active Active
-
2023
- 2023-10-03 US US18/480,442 patent/US12172994B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24671B1 (es) | Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación | |
| PH12019502264A1 (en) | Fused imidazo-piperidine jak inhibitors compound | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| CO2020001469A2 (es) | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| MX383856B (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA201791576A1 (ru) | Ингибитор jak | |
| PH12021550388A1 (en) | Process for preparing jak inhibitors and intermediates thereof | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
| MX2019014054A (es) | Profarmacos de glucuronida de inhibidores de la cinasa janus. | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| AR100095A1 (es) | Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico |